GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amarin Corp PLC (NAS:AMRN) » Definitions » Gross Profit

Amarin (Amarin) Gross Profit : $165.5 Mil (TTM As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Amarin Gross Profit?

Amarin's gross profit for the three months ended in Dec. 2023 was $45.1 Mil. Amarin's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $165.5 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Amarin's gross profit for the three months ended in Dec. 2023 was $45.1 Mil. Amarin's Revenue for the three months ended in Dec. 2023 was $74.7 Mil. Therefore, Amarin's Gross Margin % for the quarter that ended in Dec. 2023 was 60.40%.

Amarin had a gross margin of 60.40% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Amarin was 79.20%. The lowest was 53.94%. And the median was 74.38%.

Warning Sign:

Amarin Corp PLC gross margin has been in long-term decline. The average rate of decline per year is -6.2%.


Amarin Gross Profit Historical Data

The historical data trend for Amarin's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amarin Gross Profit Chart

Amarin Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 333.74 482.62 461.86 242.48 165.54

Amarin Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.60 47.93 42.67 29.82 45.12

Competitive Comparison of Amarin's Gross Profit

For the Drug Manufacturers - General subindustry, Amarin's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amarin's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amarin's Gross Profit distribution charts can be found below:

* The bar in red indicates where Amarin's Gross Profit falls into.



Amarin Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Amarin's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=306.911 - 141.37
=165.5

Amarin's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=74.713 - 29.589
=45.1

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $165.5 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Amarin's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=45.1 / 74.713
=60.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Amarin  (NAS:AMRN) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Amarin had a gross margin of 60.40% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Amarin Gross Profit Related Terms

Thank you for viewing the detailed overview of Amarin's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Amarin (Amarin) Business Description

Traded in Other Exchanges
Address
112-114 St Stephens Green, Iconic Offices, The Greenway, Block C Ardilaun Court, Dublin, IRL, D02 TD28
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its lead product includes Vascepa.
Executives
Steven B Ketchum officer: Chief Scientific Officer 2483 EAST BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
Patrick Holt director, officer: See Remarks C/O AMARIN CORPORATION, SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2 L2 D02 VK60
Oliver O'connor director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Paul Cohen director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Diane E. Sullivan director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Louis Iii Sterling director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Keith Horn director 204 STATE ROUTE 17B, P.O. BOX 5013, C/O MONTICELLO CASINO AND RACEWAY, MONTICELLO NY 12701
Patrice Eadon Bonfiglio director 488 HAVILAND ROAD, STAMFORD CT 06903
Mark Dipaolo director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Thomas Charles Reilly officer: SVP and CFO C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Aaron Berg officer: EVP, President US C/O AMARIN PHARMA, INC., 1430 ROUTE 206, BEDMINSTER NJ 07921
Karim Mikhail director, officer: President and CEO C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER NJ 08807
Olsen Per Wold director C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Murray Stewart director C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3